证券代码：688166 证券简称：博瑞医药 公告编号：2025-018 博瑞生物医药（苏州）股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"或"博瑞医药"） 第四届监事会第六次会议于 2025 年 5 月 8 日以通讯表决方式召开。本次会议通 知以及相关材料已于 2025 年 4 月 30 日以邮件方式送达公司全体监事。 本次会议应出席监事 5 名，实到 5 名，会议由何幸先生召集。本次会议的召 集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规 定。 二、监事会会议审议情况 （一）审议通过《关于调整公司 2024 年度向特定对象发行 A 股股票方案的 议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》以及《上市公司 证券发行注册管理办法》等有关法律、法规和规范性文件的规定及公司 2023 年 年度股东大会的授权，鉴于公司已实施 2023 年年度权益分派，公司拟对 2024 ...

博瑞生物医药（苏州）股份有限公司 第四届董事会独立董事第二次专门会议决议 一、独立董事专门会议召开情况 博瑞生物医药（苏州）股份有限公司（下称"公司"）第四届董事会独立董 事第二次专门会议于 2025 年 5 月 8 日以通讯表决方式召开。本次会议应出席独 立董事 3 名，实到 3 名，会议由独立董事许冬冬先生主持。本次会议的召集、召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、独立董事专门会议审议情况 1. 审议通过《关于调整公司 2024 年度向特定对象发行 A 股股票方案的议 案》 经审议，独立董事一致认为公司 2024 年度向特定对象发行 A 股股票方案调 整符合相关法律法规的规定，符合公司的发展战略及实际情况，不存在损害公司 或者中小股东权益的情形，一致同意本次发行方案调整，并同意将该议案提交公 司董事会审议，关联董事需回避表决。 表决结果：3 票同意；0 票反对；0 票弃权。 2. 审议通过《关于公司 2024 年度向特定对象发行 A 股股票预案（修订稿） 的议案》 经审议，独立董事一致认为公司《2024 年度向特定对象发行 A 股股票预案 （修订稿）》符合相关法律法 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）第四届董事会第 六次会议于 2025 年 5 月 8 日以通讯表决方式召开。本次会议通知以及相关材料 已于 2025 年 4 月 30 日以邮件方式送达公司全体董事。 本次会议应出席董事 9 名，实到 9 名，会议由袁建栋先生召集和主持。本次 会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 二、董事会会议审议情况 （一）审议通过《关于调整公司 2024 年度向特定对象发行 A 股股票方案的 议案》 证券代码：688166 证券简称：博瑞医药 公告编号：2025-017 博瑞生物医药（苏州）股份有限公司 第四届董事会第六次会议决议公告 表决结果：8 票同意；0 票反对；0 票弃权；1 票回避。 关联董事袁建栋先生回避表决。 根据《中华人民共和国公司法》《中华人民共和国证券法》以及《上市公司 证券发行注册管理办法》等有关法律、法规和规范性文件的规定及公司 2023 年 ...

Core Viewpoint - The company plans to apply for the registration and issuance of medium-term notes not exceeding 300 million yuan, with a maturity of up to 5 years, to broaden financing channels and reduce financing costs [1] Group 1 - The issuance has been approved by the company's fourth board of directors' sixth meeting and will be submitted for shareholder meeting approval [1] - The funds raised will be used for research and development investments and to supplement working capital in compliance with national laws and regulations [1]

Group 1 - The World Health Organization (WHO) plans to include weight loss medications in its essential medicines list for treating adult obesity, with guidelines expected to be released in August or September [1] - The current review by WHO's expert committee aims to provide guidance for national or regional procurement agencies to select medications that meet priority health needs [1] - The global public health policy is undergoing a significant shift in addressing the obesity epidemic [1] Group 2 - As domestic weight loss drugs approach commercialization, sales capability will be a critical factor in determining future competitive advantages for companies [2] - Companies with leading research and development progress and strong sales execution will hold advantageous positions in the commercialization competition [2] - The entire GLP-1 industry chain is expected to enter a phase of increasing prosperity due to sustained growth in end-user demand [2] Group 3 - Pro Pharmaceutical's research on the peptide-based weight loss drug (semaglutide injection) is progressing smoothly [3] - Borui Pharmaceutical has developed a dual receptor agonist (GLP-1/GLP) that can control blood sugar, promote weight loss, and treat non-alcoholic fatty liver disease [4] Group 4 - The competition in the global weight loss drug market is intensifying, particularly between Novo Nordisk and Eli Lilly [1] - Future sales performance in the weight loss drug market may not solely depend on clinical data, as Novo Nordisk's superior marketing strategies play a significant role [1] - Novo Nordisk's marketing efforts include substantial investments in promotional activities and the use of more engaging narrative scenarios [1]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-015 博瑞生物医药（苏州）股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 19 日 14 点 00 分 召开地点：江苏省苏州工业园区启月街 299 号独墅湖世尊酒店 M9 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 19 日 至2025 年 5 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [4]. Core Viewpoints - The domestic weight loss drug market is entering commercialization, emphasizing the importance of sales capabilities for companies [1][19]. - The competition in the global weight loss drug market is intensifying, particularly between Novo Nordisk and Eli Lilly, where marketing strategies play a crucial role in sales performance [19][23]. - Companies with advanced R&D progress and strong sales execution will hold competitive advantages in the commercialization phase of weight loss drugs [1][19]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 1.16%, outperforming the CSI 300 index by 0.77 percentage points but underperforming the ChiNext index by 1.08 percentage points, ranking 15th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Healthcare Index increased by 8.44%, outperforming the Hang Seng Index by 6.12 percentage points [1][15]. Company Updates - Recent clinical application updates include Baiyi Shenzhou's injection BGB-B2033 and Nuo Cheng Jian Hua's injection ICP-B794, both newly undertaken [27]. - Ongoing clinical trials include Bo Rui Pharmaceutical's BGM0504 and Hua Dong Pharmaceutical's HDM1002, currently in Phase III [27]. Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: in-hospital payments, out-of-pocket payments, and overseas payments [2]. - Key recommended companies include Heng Rui Pharmaceutical, Mai Rui Medical, and United Imaging Healthcare [2]. Company Profit Forecasts and Valuation - Heng Rui Pharmaceutical is rated "Accumulate" with a projected EPS of 0.99 yuan for 2024 and a PE ratio of 51 [3]. - Mai Rui Medical is rated "Buy" with a projected EPS of 11.47 yuan for 2024 and a PE ratio of 19 [3]. - United Imaging Healthcare is also rated "Buy" with a projected EPS of 2.88 yuan for 2024 and a PE ratio of 44 [3].

Investment Rating - The report maintains a "Buy" rating for the company [2]. Core Views - The company focuses on the research and development of metabolic drugs, with new pipeline additions including oral BGM0504 and Amylin analog BGM1812. The current strategy emphasizes developing innovative drugs with global intellectual property rights in the metabolic disease field [5][17]. - The company reported a revenue of 1.283 billion yuan in 2024, an increase of 8.74% year-on-year, while the net profit attributable to the parent company was 189 million yuan, a decrease of 6.57% [5]. - The company expects revenues of 1.444 billion yuan in 2025, with a year-on-year growth of 12.6%, and net profits of 253 million yuan, reflecting a growth of 33.7% [5]. Summary by Sections Market Performance - The company's stock price has shown a relative increase compared to the CSI 300 index, with absolute growth rates of 11.71% over 1 month, 17.10% over 2 months, and 48.00% over 3 months [4]. Financial Data - In 2024, the company achieved a gross margin of 58.62%, an increase of 2.5 percentage points year-on-year. The R&D expenses for 2024 were 297 million yuan, a year-on-year increase of 19.65%, reflecting the company's commitment to a "R&D-driven" strategy [5][6]. Product Pipeline - The company is advancing its innovative drug development, with BGM0504 injection for type 2 diabetes and weight loss currently in phase III clinical trials in China, and the oral formulation BGM0504 is in preclinical stages [5][9][17]. - BGM1812, an Amylin analog, is also in the pipeline, targeting metabolic diseases and expected to complement GLP-1 drugs for enhanced weight loss effects [17][18]. Revenue Forecast - The company forecasts revenues of 1.641 billion yuan in 2026 and 1.889 billion yuan in 2027, with corresponding net profits of 297 million yuan and 363 million yuan, indicating a strong growth trajectory [6].

关于召开 2024 年度暨 2025 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 12 日（星期一）下午 13:00-14:30 证券代码：688166 证券简称：博瑞医药 公告编号：2025-016 博瑞生物医药（苏州）股份有限公司 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络文字互动 投资者可于 2025 年 4 月 30 日（星期三）至 5 月 9 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bright-gene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）已于 2025 年 4 月 3 日发布公司 2024 年年度报告，并于 2025 年 4 月 ...

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company focuses on the research and development of metabolic drugs, with new pipeline additions including oral BGM0504 and Amylin analog BGM1812 [5] - The company reported a revenue of 1.283 billion yuan in 2024, an increase of 8.74%, while the net profit attributable to the parent company was 189 million yuan, a decrease of 6.57% [5] - The company expects revenue growth of 12.6%, 13.7%, and 15.1% for the years 2025, 2026, and 2027, respectively, with net profit growth of 33.7%, 17.6%, and 22.0% during the same period [5] Financial Performance - In 2024, the company achieved a gross margin of 58.62%, an increase of 2.5 percentage points year-on-year [5] - The R&D expenses for 2024 were 297 million yuan, a year-on-year increase of 19.65%, reflecting the company's commitment to a "R&D-driven" strategy [5] - The company’s total assets were reported at 5.285 billion yuan, with a total market value of approximately 18.576 billion yuan [6] Market Comparison - The company’s stock performance showed an absolute increase of 11.71% over one month, 17.10% over two months, and 48.00% over three months [4] - Compared to the CSI 300 index, the company outperformed with a relative increase of 15.09%, 21.46%, and 49.19% over the same periods [4] Research and Development Focus - The company is developing BGM0504, an oral formulation that aims to overcome the challenges of oral peptide delivery, which has high technical barriers globally [9][10] - BGM1812, an Amylin analog, is positioned to complement GLP-1 drugs in weight management and blood sugar control [17] - The company is advancing its clinical trials for BGM0504, with both Type 2 diabetes and weight loss indications progressing as planned [5]